Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis.
The development of therapeutic alternatives to treat leishmaniasis has received considerable attention. The present study aimed to investigate the efficacy of the Agaricus blazei Murill water extract (AbM) to treat BALB/c mice infected with Leishmania amazonensis. First, a dose-titration curve was performed. The most well-defined concentration able to induce the most effective results in the infected animals, considering a daily administration of the product, was that of 100 mg kg(-1) day(-1). In this context, the AbM was administered orally, beginning on day 0 up to 20 days postinfection. Additional animals were treated with amphotericin B (AmpB, 5 mg kg(-1) day(-1)) by peritoneal route for the same period of time, while the control group received distilled water. The animals were evaluated at 14 weeks post-infection, at which time the parasitological and immunological parameters were analyzed. Mice treated with the AbM presented a 60% reduction in the inflammation of infected footpads as compared to untreated control-infected mice. Moreover, in the treated mice, as compared to the untreated controls, approximately 60 and 66% reductions could be observed in the parasite burdens of the footpad and draining lymph nodes, respectively. In addition, no parasites could be detected in the spleen of treated mice at week 14 postinfection. These treated animals produced significantly higher levels of interferon gamma (IFN-γ) and nitric oxide (NO), higher levels of parasite-specific IgG2a isotype antibodies, and lower levels of interleukin (IL)-4, and IL-10 in the spleen and lymph node cell cultures than did the controls. Differences could be observed by comparing animals treated with AbM to those treated with AmpB, as indicated by a significant reduction in tissue parasitism, higher levels of IFN-γ and NO, and lower levels of IL-4 and IL-10, as well as by a decreased hepatic toxicity. In conclusion, the present study's data show that the A. blazei Murill water extract presents a high potential for the treatment of leishmaniasis, although additional studies on mice, as well as on other mammal hosts, are warranted in an attempt to determine this extract's true efficacy as compared to other known therapeutic products.
Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, 31.270-901 Belo Horizonte, Minas Gerais, Brazil.
Diogo G
DG
Valadares
Mariana C
MC
Duarte
Laura
L
Ramírez
Miguel A
MA
Chávez-Fumagalli
Paula S
PS
Lage
Vivian T
VT
Martins
Lourena E
LE
Costa
Tatiana G
TG
Ribeiro
Wiliam C B
WC
Régis
Manuel
M
Soto
Ana Paula
AP
Fernandes
Carlos A P
CA
Tavares
Eduardo A F
EA
Coelho
D000284:Administration, Oral; D000364:Agaricus / Q000737:chemistry*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000302:isolation & purification; D001688:Biological Products / Q000008:administration & dosage* / Q000302:isolation & purification; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005528:Foot / Q000469:parasitology; D006801:Humans; D007891:Leishmania / Q000302:isolation & purification; D007896:Leishmaniasis / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D008099:Liver / Q000469:parasitology; D008198:Lymph Nodes / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000378:metabolism; D059208:Parasite Load; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D001688:Biological Products; D016207:Cytokines; D009569:Nitric Oxide